Novartis notifies about Phase III COMBI-I study to treat skin cancer

By Nikita Chaurasia  | Date: 2020-08-24

Novartis notifies about Phase III COMBI-I study to treat skin cancer

Reportedly, Novartis made an announcement that the COMBI-I study in its third phase that does evaluation of investigational immunotherapy spartalizumab (PDR001), combined with the targeted therapies Mekinist (trametinib) and Tafinlar (dabrafenib) did not produce a primary result of progression-free, investigator-assessed survival.

As per the trusted sources, the trail was conducted on untreated patients with metastatic (Stage IV) BRAF V600 or unresectable (Stage IIIC) mutation-positive cutaneous melanoma, in comparison with Tafinlar + Mekinist treatment alone. Tafinlar and Mekinist are medicines prescribed in combination to treat patients with skin cancer- melanoma.

John Tsai, MD, Chief Medical Officer and Head of Global Drug Development at Novartis states that although the COMBI-I trial did not get to its primary outcome, the report’s analysis offers some important insights of its part like the investigational immunotherapy spartalizumab could possibly contribute to the future cancer therapy combinations. Besides this, it also highlights the significance of Tafinlar + Mekinist for these patients as estimated in the past.

He further added that Novartis is fully dedicated towards curing melanoma patients through ongoing study and they would continue to provide the approved combination therapy Tafinlar + Mekinist to patients across the globe.

He added that they at Novartis extend gratitude to the patients and investigators who took part in the COMBI-I study and claimed that their collaboration has raised understanding of spartalizumab and its potential role in future cancer treatments at Novartis.

Reportedly, COMBI-I study investigators and people at Novartis will continue to analyze the data to gain more information from the results, which are likely to be taken forward to a presentation at a future medical meeting.

Novartis continues to search for more uses of immunotherapy in cancer treatment, along with the latest ongoing development of spartalizumab, across a plethora of tumors.  

Source credits-

https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Tatas in plans to acquire Bisleri in a deal worth USD 856 million

Tatas in plans to acquire Bisleri in a deal worth USD 856 million

By Nikita Chaurasia

India's fast-moving consumer goods company, Tata Consumer Products Ltd is reportedly all set to acquire drink company, Bisleri International in a deal worth USD 856 million (₹7000 crores), reported the packaged water makers chairman, Ramesh...

Ukio raises $28M to offer comfort to working professionals across Europe

Ukio raises $28M to offer comfort to working professionals across Europe

By Nikita Chaurasia

Ukio, an apartment rental agency in Barcelona, Spain, has reportedly raised $28 million (€27 million) in a Series A round of funding. Apparently, the cash injection consists of over $17.5 million (€17 million) in equity and more than $10...

Amazon’s AWS unveils 2nd infrastructure region in Hyderabad, India

Amazon’s AWS unveils 2nd infrastructure region in Hyderabad, India

By Nikita Chaurasia

IT service management company, Amazon Web Services, Inc. (AWS), has recently announced the unveiling of another leading AWS infrastructure region in India, the AWS Asia Pacific (Hyderabad) Region. Starting this week, the startups, developers, ente...

Beijing reports increase in COVID-19 cases after first death in six months

Beijing reports increase in COVID-19 cases after first death in six months

By Nikita Chaurasia

World's most populous country, China has recently reported the fatalities of three people in Beijing as the first fatalities from coronavirus in the last six months, with the rise in recorded new cases despite following the strictest zero-COVID p...

India flags concern as rich nations want to extend mitigation to agriculture

India flags concern as rich nations want to extend mitigation to agriculture

By Nikita Chaurasia

During the ongoing COP27 (UN climate summit) in Egypt, India has countered the developed world’s effort for extending the scope of mitigation to agriculture, stating that rich nations are not seeking to mitigate emissions by modifying their lif...